The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Sorafenib-Global Market Insights and Sales Trends 2024
Synopsis
Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer
The global Sorafenib market size is expected to reach US$ 786.5 million by 2029, growing at a CAGR of -2.2% from 2023 to 2029. The market is mainly driven by the significant applications of Sorafenib in various end use industries. The expanding demands from the Kidney Cancer, Liver Cancer, Thyroid Cancer and Other, are propelling Sorafenib market. Patented Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Generic Drugs segment is estimated at % CAGR for the next seven-year period.
Sorafenib is a targeted therapy used in the treatment of various cancers, including liver, kidney, and thyroid cancer. Factors driving market growth include the increasing incidence of these cancers, advancements in cancer treatment options, and the effectiveness of sorafenib in improving patient outcomes. The market is highly competitive, with several pharmaceutical companies manufacturing and marketing sorafenib. However, challenges such as high treatment costs, potential side effects, and the emergence of alternative therapies may hinder market growth. Nonetheless, the sorafenib market holds promising opportunities, driven by the growing global burden of cancer and the continuous research and development efforts to enhance the therapeutic potential of sorafenib.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Sorafenib, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Sorafenib market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Sorafenib market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Sorafenib sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Sorafenib covered in this report include Bayer, Natco Pharma, Cipla and Mylan, etc.
The global Sorafenib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Natco Pharma
Cipla
Mylan
Global Sorafenib market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sorafenib market, Segment by Type:
Patented Drugs
Generic Drugs
Global Sorafenib market, by Application
Kidney Cancer
Liver Cancer
Thyroid Cancer
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Sorafenib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Sorafenib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer
The global Sorafenib market size is expected to reach US$ 786.5 million by 2029, growing at a CAGR of -2.2% from 2023 to 2029. The market is mainly driven by the significant applications of Sorafenib in various end use industries. The expanding demands from the Kidney Cancer, Liver Cancer, Thyroid Cancer and Other, are propelling Sorafenib market. Patented Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Generic Drugs segment is estimated at % CAGR for the next seven-year period.
Sorafenib is a targeted therapy used in the treatment of various cancers, including liver, kidney, and thyroid cancer. Factors driving market growth include the increasing incidence of these cancers, advancements in cancer treatment options, and the effectiveness of sorafenib in improving patient outcomes. The market is highly competitive, with several pharmaceutical companies manufacturing and marketing sorafenib. However, challenges such as high treatment costs, potential side effects, and the emergence of alternative therapies may hinder market growth. Nonetheless, the sorafenib market holds promising opportunities, driven by the growing global burden of cancer and the continuous research and development efforts to enhance the therapeutic potential of sorafenib.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Sorafenib, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Sorafenib market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Sorafenib market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Sorafenib sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Sorafenib covered in this report include Bayer, Natco Pharma, Cipla and Mylan, etc.
The global Sorafenib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Natco Pharma
Cipla
Mylan
Global Sorafenib market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sorafenib market, Segment by Type:
Patented Drugs
Generic Drugs
Global Sorafenib market, by Application
Kidney Cancer
Liver Cancer
Thyroid Cancer
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Sorafenib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Sorafenib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Sorafenib Market Overview
1.1 Sorafenib Product Overview
1.2 Sorafenib Market Segment by Type
1.2.1 Patented Drugs
1.2.2 Generic Drugs
1.3 Global Sorafenib Market Size by Type
1.3.1 Global Sorafenib Market Size Overview by Type (2018-2029)
1.3.2 Global Sorafenib Historic Market Size Review by Type (2018-2023)
1.3.3 Global Sorafenib Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Sorafenib Sales Breakdown by Type (2018-2023)
1.4.2 Europe Sorafenib Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Sorafenib Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Sorafenib Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Sorafenib Sales Breakdown by Type (2018-2023)
2 Global Sorafenib Market Competition by Company
2.1 Global Top Players by Sorafenib Sales (2018-2023)
2.2 Global Top Players by Sorafenib Revenue (2018-2023)
2.3 Global Top Players by Sorafenib Price (2018-2023)
2.4 Global Top Manufacturers Sorafenib Manufacturing Base Distribution, Sales Area, Product Type
2.5 Sorafenib Market Competitive Situation and Trends
2.5.1 Sorafenib Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Sorafenib Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Sorafenib as of 2022)
2.7 Date of Key Manufacturers Enter into Sorafenib Market
2.8 Key Manufacturers Sorafenib Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Sorafenib Status and Outlook by Region
3.1 Global Sorafenib Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Sorafenib Historic Market Size by Region
3.2.1 Global Sorafenib Sales in Volume by Region (2018-2023)
3.2.2 Global Sorafenib Sales in Value by Region (2018-2023)
3.2.3 Global Sorafenib Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Sorafenib Forecasted Market Size by Region
3.3.1 Global Sorafenib Sales in Volume by Region (2024-2029)
3.3.2 Global Sorafenib Sales in Value by Region (2024-2029)
3.3.3 Global Sorafenib Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Sorafenib by Application
4.1 Sorafenib Market Segment by Application
4.1.1 Kidney Cancer
4.1.2 Liver Cancer
4.1.3 Thyroid Cancer
4.1.4 Other
4.2 Global Sorafenib Market Size by Application
4.2.1 Global Sorafenib Market Size Overview by Application (2018-2029)
4.2.2 Global Sorafenib Historic Market Size Review by Application (2018-2023)
4.2.3 Global Sorafenib Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Sorafenib Sales Breakdown by Application (2018-2023)
4.3.2 Europe Sorafenib Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Sorafenib Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Sorafenib Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Sorafenib Sales Breakdown by Application (2018-2023)
5 North America Sorafenib by Country
5.1 North America Sorafenib Historic Market Size by Country
5.1.1 North America Sorafenib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Sorafenib Sales in Volume by Country (2018-2023)
5.1.3 North America Sorafenib Sales in Value by Country (2018-2023)
5.2 North America Sorafenib Forecasted Market Size by Country
5.2.1 North America Sorafenib Sales in Volume by Country (2024-2029)
5.2.2 North America Sorafenib Sales in Value by Country (2024-2029)
6 Europe Sorafenib by Country
6.1 Europe Sorafenib Historic Market Size by Country
6.1.1 Europe Sorafenib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Sorafenib Sales in Volume by Country (2018-2023)
6.1.3 Europe Sorafenib Sales in Value by Country (2018-2023)
6.2 Europe Sorafenib Forecasted Market Size by Country
6.2.1 Europe Sorafenib Sales in Volume by Country (2024-2029)
6.2.2 Europe Sorafenib Sales in Value by Country (2024-2029)
7 Asia-Pacific Sorafenib by Region
7.1 Asia-Pacific Sorafenib Historic Market Size by Region
7.1.1 Asia-Pacific Sorafenib Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Sorafenib Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Sorafenib Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Sorafenib Forecasted Market Size by Region
7.2.1 Asia-Pacific Sorafenib Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Sorafenib Sales in Value by Region (2024-2029)
8 Latin America Sorafenib by Country
8.1 Latin America Sorafenib Historic Market Size by Country
8.1.1 Latin America Sorafenib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Sorafenib Sales in Volume by Country (2018-2023)
8.1.3 Latin America Sorafenib Sales in Value by Country (2018-2023)
8.2 Latin America Sorafenib Forecasted Market Size by Country
8.2.1 Latin America Sorafenib Sales in Volume by Country (2024-2029)
8.2.2 Latin America Sorafenib Sales in Value by Country (2024-2029)
9 Middle East and Africa Sorafenib by Country
9.1 Middle East and Africa Sorafenib Historic Market Size by Country
9.1.1 Middle East and Africa Sorafenib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Sorafenib Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Sorafenib Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Sorafenib Forecasted Market Size by Country
9.2.1 Middle East and Africa Sorafenib Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Sorafenib Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Bayer
10.1.1 Bayer Company Information
10.1.2 Bayer Introduction and Business Overview
10.1.3 Bayer Sorafenib Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Bayer Sorafenib Products Offered
10.1.5 Bayer Recent Development
10.2 Natco Pharma
10.2.1 Natco Pharma Company Information
10.2.2 Natco Pharma Introduction and Business Overview
10.2.3 Natco Pharma Sorafenib Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Natco Pharma Sorafenib Products Offered
10.2.5 Natco Pharma Recent Development
10.3 Cipla
10.3.1 Cipla Company Information
10.3.2 Cipla Introduction and Business Overview
10.3.3 Cipla Sorafenib Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Cipla Sorafenib Products Offered
10.3.5 Cipla Recent Development
10.4 Mylan
10.4.1 Mylan Company Information
10.4.2 Mylan Introduction and Business Overview
10.4.3 Mylan Sorafenib Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Mylan Sorafenib Products Offered
10.4.5 Mylan Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Sorafenib Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Sorafenib Industrial Chain Analysis
11.4 Sorafenib Market Dynamics
11.4.1 Sorafenib Industry Trends
11.4.2 Sorafenib Market Drivers
11.4.3 Sorafenib Market Challenges
11.4.4 Sorafenib Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Sorafenib Distributors
12.3 Sorafenib Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
